Evidence map›Paper›PMID 37582953›Full record

ArticleZeitschrift fur Rheumatologie2024

High- and low-dose cyclophosphamide in Egyptian lupus nephritis patients: a multicenter retrospective analysis.

Mohamed Momtaz A Elaziz, Sherif M Gamal, Ahmed Fayed, Mohammed Hassan Abu-Zaid, Shada A Ghoniem, Doaa A Teleb

Open access · hybridAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Zeitschrift fur Rheumatologie, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 1 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Mohamed Momtaz A ElazizDepartment of Internal Medicine, Nephrology Unit, Cairo University Hospital, Cairo, Egypt.ORCID http://orcid.org/0000-0003-0170-4205
Sherif M GamalRheumatology and Rehabilitation Department, Faculty of medicine, Cairo University Hospital, Cairo University, Al Kasr Al Aini, Old Cairo, Cairo Governorate, 4240310, Cairo, Egypt.ORCID http://orcid.org/0000-0002-2663-4111
Ahmed FayedDepartment of Internal Medicine, Nephrology Unit, Cairo University Hospital, Cairo, Egypt.ORCID http://orcid.org/0000-0002-6041-4016
Mohammed Hassan Abu-ZaidRheumatology and Rehabilitation Department, Tanta University Hospital, Tanta, Egypt.ORCID http://orcid.org/0000-0001-8436-8598
Shada A GhoniemRheumatology and Rehabilitation Department, Faculty of medicine, Cairo University Hospital, Cairo University, Al Kasr Al Aini, Old Cairo, Cairo Governorate, 4240310, Cairo, Egypt. shadaghoniem@yahoo.com.ORCID http://orcid.org/0000-0002-3338-7585
Doaa A TelebRheumatology and Rehabilitation Department, Faculty of medicine, Cairo University Hospital, Cairo University, Al Kasr Al Aini, Old Cairo, Cairo Governorate, 4240310, Cairo, Egypt.ORCID http://orcid.org/0000-0001-8712-6914
Cairo University · EGTanta University Hospital · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLupus nephritis (LN) is a common serious presentation of systemic lupus erythematosus. Cyclophosphamide (CYC) and mycophenolate mofetil (MMF) are listed as the first-line drugs in induction therapy for LN.

objectiveThis study aimed to compare high- and low-dose CYC in a cohort of Egyptian LN patients. PATIENTS AND

methodsThe data of 547 patients with class III/IV active LN who received CYC as induction therapy were retrospectively analyzed. Whereas 399 patients received 6‑monthly 0.5-1 g/m

resultsAfter 48 months, the proportion of patients maintaining normal creatinine levels was higher in the group receiving induction therapy with high-dose CYC (67.9%, 60.4%, p = 0.029), and these patients also had higher proteinuria remission at 36 (26.6%, 14.8%, p = 0.014) and 48 months (24.3%, 12.8%, p = 0.006). Comparison of patient outcomes according to both induction and maintenance therapy showed the best results in patients who received high-dose CYC and continued MMF as maintenance therapy.

conclusionHigh- and low-dose CYC are comparable in early phases of treatment. However, after a longer duration of follow-up, high-dose CYC was associated with higher remission rates in the current cohort.

Indexed as

Lupus NephritisCyclophosphamideEgyptHumansImmunosuppressive AgentsMycophenolic AcidRemission InductionRetrospective StudiesTreatment OutcomeCyclophosphamideImmunosuppressive AgentsMycophenolic AcidInduction therapyProteinuriaRemissionRenal functionRenal outcomeSystemic lupus erythematosus

Identifiers

PMID37582953
PMCPMC10879243
OpenAlexW4385829062

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.